France's HRA Pharma SA is looking to sharpen its focus on expansion in the global consumer healthcare market by shifting its orphan drug portfolio into a newly-created affiliate company.
HRA Pharma Rare Diseases will be tasked with the development of its portfolio of drugs that address Cushing’s Syndrome (Metopirone, Ketoconazole HRA) and Adrenal Cortical Carcinoma (Lysodren), while its parent...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?